Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Rebukes Egalet's Reliance On OxyContin Postmarketing Data

Executive Summary

Arymo ER sponsor's consultants said Purdue's postmarketing data on its reformulated oxycodone establish a link between abuse-deterrent properties and reduced real-world abuse, but FDA says it disagreed with the conclusion in the context of an OxyContin labeling supplement.

Advertisement

Related Content

Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register